Clinical Trials Browser

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

Clinical Trials

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

PNOC020

CLOVER-2

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

PNOC017

IMPACT

Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

IMPACT

RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)

Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma

rQNestin

Phase I Study of APX005M in Pediatric Central Nervous System Tumors

Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

Surgical Nivolumab And Ipilimumab For Recurrent GBM

Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Peds CHAMP1ON

OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma

XACT-Fe-GBM-01

Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma

ETAPA I

Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

M032-HSV-1

Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma

INTERCEPT-H3

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)

A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma

C134-HSV-1

MK-6482-001

Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

D2C7-IT With Atezolizumab for Recurrent Gliomas

Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma

Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)